• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
BioForm Medical, Inc., a medical aesthetics company, focuses on developing and commercializing products that are used by physicians to enhance a patient's appearance. Its core product is Radiesse, an injectable dermal filler used to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency; and Coaptite as a peri-urethral bulking agent to treat women, who has stress urinary incontinence due to poorly functioning urethral sphincter muscles. In addition, it has licensed Aethoxysklerol, an injectable sclerosing drug for the treatment of varicose veins; and BioGlue, a surgical adhesive product. BioForm Medical markets Radiesse to dermatologists, plastic surgeons, facial plastic surgeons, and other physicians performing cosmetic procedures in the United States.
Please sign in first
none
none
none
| Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
|---|---|---|---|---|
|
No longer subject to file | 2010-02-16 | 0 | |
|
CONDON DENNIS E PRES & CHIEF BUSINESS OFFICER |
|
0 | 2010-02-16 | 0 |
|
0 | 2010-02-16 | 0 | |
|
LAI N C JOSEPH HELEN & JOSEPH LAI IRREVOCABLE TRUST DATED DECEMBER 17 1999 NAICHIU JOSEPH LAI REVOCABLE TRUST |
|
No longer subject to file | 2010-02-16 | 0 |
|
No longer subject to file | 2010-02-16 | 0 | |
|
No longer subject to file | 2010-02-16 | 0 | |
|
BASTA STEVEN L CHIEF EXECUTIVE OFFICER STEVEN L BASTA TR UA 08 01 1991 STEVEN L BASTA TRUST |
|
0 | 2010-02-16 | 0 |
|
No longer subject to file | 2010-02-16 | 0 | |
|
GRIDLEY ADAM SVP, CORPORATE DEVELOPMENT |
|
0 | 2010-02-16 | 0 |
|
No longer subject to file | 2010-02-16 | 0 | |
|
LWEE FREDERICK VP OF FINANCE, PRINCIPAL FIN.O |
|
0 | 2010-02-16 | 0 |
|
VINE ACQUISITION CORP. |
|
47,456,721 | 2010-02-16 | 0 |
|
0 | 2010-02-16 | 0 | |
|
0 | 2010-02-16 | 0 | |
|
VOGT MATTHIAS A TREASURER & SECRETARY |
|
0 | 2010-02-16 | 0 |
|
ZUEGEL MARTIN PRESIDENT |
|
0 | 2010-02-16 | 0 |
|
BIOASIA INVESTMENTS LLC BIOTECHNOLOGY DEVELOPMENT FUND LP |
|
429,492 | 2010-01-19 | 0 |
|
BIOTECHNOLOGY DEVELOPMENT FUND IV AFFILIATES LP BIOTECHNOLOGY DEVELOPMENT FUND IV LP BIOASIA CROSSOVER FUND LP |
|
1,585,810 | 2010-01-19 | 0 |
|
2,558,713 | 2010-01-19 | 0 | |
|
BASTA STEVEN L CHIEF EXECUTIVE OFFICER |
|
927,086 | 2009-11-05 | 0 |
|
FLOYD JAMES D INTERIM CFO |
|
0 | 2009-02-06 | 0 |
|
BERTOCCI DEREK A CFO |
|
0 | 2008-07-09 | 0 |
|
ERICKSON DEAN A VP MANUFACTURING, GM OF WI OP |
|
0 | 2008-07-09 | 0 |
|
SHELTON JASON VP, MARKETING |
|
0 | 2008-07-09 | 0 |
|
DE LANGE JAAP VICE PRESIDENT |
|
0 | 2008-07-09 | 0 |
|
HOLMES CHRIS VP, SALES |
|
0 | 2008-07-09 | 0 |
|
LEUNG JOSEPH WING KONG CHAN KAM POR |
|
3,310,339 | 2007-11-09 | 0 |
|
6,338,599 | 2007-11-09 | 0 | |
|
ESSEX WOODLANDS HEALTH VENTURES FUND VI L P ESSEX WOODLANDS HEALTH VENTURES VI, LLC ESSEX WOODLANDS HEALTH VENTURES VI, LP |
|
7,087,295 | 2007-11-09 | 0 |
|
6,338,599 | 2007-11-09 | 0 | |
|
1,907,542 | 2007-11-09 | 0 | |
|
TEKNOINVEST VIII KS TEKNOINVEST VIII GP KS |
|
2,906,710 | 2007-11-09 | 0 |
|
WELLS JEFFREY MARK SVP OF PRODUCT DEVELOPMENT |
|
0 | 2007-11-06 | 0 |
| Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| No current insider transactions | ||||||||||||||||
* -
| Code | Definition |
|---|---|
| A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
| C | Conversion of derivative security |
| D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
| E | Expiration of short derivative position |
| F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
| G | Bona fide gift |
| H | Expiration (or cancellation) of long derivative position with value received |
| I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
| J | Other acquisition or disposition |
| L | Small acquisition under Rule 16a-6 |
| M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
| O | Exercise of out-of-the-money derivative security |
| P | Open market or private purchase of non-derivative or derivative security |
| S | Open market or private sale of non-derivative or derivative security |
| U | Disposition pursuant to a tender of shares in a change of control transaction |
| W | Acquisition or disposition by will or the laws of descent and distribution |
| X | Exercise of in-the-money or at-the-money derivative security |
| Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
| Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
|---|
| Holder | Issuer | Net Short Position | Position Date | Origin |
|---|
